Merck KGaA keeps US tariff surcharge while pausing China fees; cuts sales guidance to €20.9-22.4B amid economic uncertainty.

Biohaven said late Wednesday that the FDA would be delaying the PDUFA date for its neurodegenerative disease therapy ...

HHS Secretary Robert F. Kennedy Jr. faced hours of congressional grilling on Wednesday over his proposed budget cuts and ...

AbbVie partners with ADARx Pharmaceuticals in $335M upfront deal for siRNA tech collaboration across neuroscience, immunology ...

Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several ...

Jiang­su Hen­grui, a 55-year-old drug­mak­er that has be­come one of Chi­na’s lead­ing forces in biotech, ex­pects net pro­ceeds of about 9.4 bil­lion Hong Kong dol­lars … ...

GSK to pay $1.2B upfront to Boston Pharmaceuticals for efimosfermin alfa, a MASH drug candidate. Deal includes $800M in ...

Novo Nordisk is partnering with Septerna in a $2B+ deal to develop oral small molecules for obesity and diabetes, focusing on ...

The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations ...

Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...

An order from a federal appeals court has kicked the battle wide open again over who holds the key patents for CRISPR-Cas9, a ...

Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...